Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a ...

The market expects Sage Therapeutics, Inc. (SAGE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

On the other hand, Verve Therapeutics VERV skyrocketed on positive data from a cholesterol study. Shares of Bristol Myers Squibb declined after the company announced that the late-stage ODYSSEY ...

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...

Assess today's live Priority Income Fund Inc Pref Series D (PRIF_pd) share price, performance and insights using our live NYSE: PRIF_pd stock exchange data. Analyse the historical data and Priority ...